Serum lipopolysaccharide neutralizing capacity in ischemic stroke. by Leskelä, Jaakko et al.
RESEARCH ARTICLE
Serum lipopolysaccharide neutralizing
capacity in ischemic stroke
Jaakko LeskeläID
1, Milla Pietiäinen1, Anton Safer2, Markku Lehto3, Jari Metso4,
Ernst Malle5, Florian Buggle6, Heiko Becher7,8, Jouko Sundvall9, Armin J. Grau6, Pirkko
J. PussinenID
1☯*, Frederick Palm10☯
1 Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland, 2 Institute of Global Health,
University of Heidelberg, Heidelberg, Germany, 3 Folkhälsan Institute of Genetics, Folkhälsan Research
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Periodontitis is associated with increased serum lipopolysaccharide (LPS) activity, which
may be one mechanism linking periodontitis with the risk of cardiovascular diseases. As
LPS-carrying proteins including lipoproteins modify LPS-activity, we investigated the deter-
minants of serum LPS-neutralizing capacity (LPS-NC) in ischemic stroke. The association
of LPS-NC and Aggregatibacter actinomycetemcomitans, a major microbial biomarker in
periodontitis, was also investigated.
Materials and methods
The assay to measure LPS-NC was set up by spiking serum samples with E. coli LPS. The
LPS-NC, LPS-binding protein (LBP), soluble CD14 (sCD14), lipoprotein profiles, apo(lipo-
protein) A-I, apoB, and phospholipid transfer protein (PLTP) activity, were determined in 98
ischemic stroke patients and 100 age- and sex-matched controls. Serum and saliva immune
response to A. actinomycetemcomitans, its concentration in saliva, and serotype-distribu-
tion were examined.
Results
LPS-NC values ranged between 51–83% in the whole population. Although several of the
LPS-NC determinants differed significantly between cases and controls (PLTP, sCD14,
apoA-I, HDL-cholesterol), the levels did not (p = 0.056). The main determinants of LPS-NC
were i) triglycerides (β = -0.68, p<0.001), and ii) HDL cholesterol (0.260, <0.001), LDL cho-
lesterol (-0.265, <0.001), PLTP (-0.196, 0.011), and IgG against A. actinomycetemcomitans
(0.174, 0.011). Saliva A. actinomycetemcomitans concentration was higher [log mean (95%
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CI), 4.39 (2.35–8.19) vs. 10.7 (5.45–21) genomes/ml, p = 0.023) and serotype D more fre-
quent (4 vs. 0%, p = 0.043) in cases than controls. Serotypeablity or serotypes did not, how-
ever, relate to the LPS-NC.
Conclusion
Serum LPS-NC comprised low PLTP-activity, triglyceride and LDL cholesterol concentra-
tions, as well as high HDL cholesterol and IgG against A. actinomycetemcomitans. The
present findings let us to conclude that LPS-NC did not associate with stroke.
Introduction
The endotoxin, lipopolysaccharide (LPS) is an important virulence factor of gram-negative
bacteria. The lipid A integrates LPS into the outer membrane of the bacterial cell and is mainly
responsible for the toxicity of the molecule, inducing physiological symptoms of illness, such
as fever, muscle aches, and nausea. The O-antigen is the most variable structure of the mole-
cule and a potent antigen in acquired immunity.
The presence of LPS in the circulation, i.e. endotoxemia, is associated with increased risk of
cardiometabolic disorders, diabetes, and kidney diseases [1–7]. The recovered LPS-activity in
the circulation varies between the moderate increases found in “metabolic endotoxemia” to
more than a hundred-fold amplified activities found in sepsis [8, 9]. The main endogenous
origin of endotoxins is the gastrointestinal microbiota, while local inflammation or dietary
challenge is probably a prerequisite for endotoxemia [5, 10, 11]. For example, periodontitis,
which is dysbiosis-driven chronic inflammation in tooth-supporting tissues, may contribute
to endotoxemia by bleeding gums and saliva [11, 12]. One of the most studied microbial
biomarkers of periodontitis is the serologically heterogeneous Aggregatibacter actinomycetem-
comitans. The serotypes of this species are characterized by structural differences in the O-
antigen of LPS [13]. Diverse serotypes may differ in immunogenicity, which probably plays a
role in both periodontitis and cardiovascular diseases [14].
During endotoxemia, LPS can be recovered in bacterial cell walls, fragments of bacterial
outer membrane, bound to bacterial or host proteins, or in blood cells [15]. The predominant
LPS fraction is associated with circulating plasma lipoproteins [16], especially high density
lipoproteins (HDL), which contribute to the detoxification of LPS activity [17]. The distribu-
tion of circulating LPS may, however, differ between inflammatory, infectious, or metabolic
diseases [18–20]. Therefore, the blood capacity to neutralize LPS activity depends on inflam-
matory status, lipoprotein and apolipoprotein profile, and concentrations of specific LPS-
transferring proteins [21–23], such as phospholipid transfer protein (PLTP), LPS-binding
protein (LBP), and soluble (s)CD14 [24]. Previous studies revealed lower LPS-neutralizing
capacity (LPS-NC) in patients with alcoholic liver disease [25] or inflammatory bowel disease
[26] when compared to controls. In these studies a qualitative gel-clot Limulus Amebocyte
Lysate assay (LAL-assay) with increasing amounts of spiked LPS in the sample have been used
to measure LPS-NC. While the gel-clot LAL-assay may be considered a useful method, the
chromogenic LAL-assay has become the preferential technique to detect LPS-activity.
Endotoxemia is associated with cardiovascular diseases, such as myocardial infarction (MI),
coronary artery disease events, and stroke [1–3, 5]. As no data on LPS-NC has been reported
in any of these diseases, the present study aimed to investigate LPS-NC in a case-control study
of ischemic stroke using the quantitative LAL-assay with a chromogenic substrate.
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Materials and methods
Population
The present population is a subsample of the larger GenesiS study, a case-control study on
genetic, socioeconomic, and infectious determinants of ischemic stroke [27]. Patients between
the age of 18 and 80 years with a first-ever ischemic stroke were recruited. The patients with
signs of acute infections were excluded. In addition to clinical examination, an interview using
a structured questionnaire was conducted and blood samples were collected.
Healthy controls were selected from a random sample of inhabitants living in the coverage
area of the registry, based on the official population registry. Persons with previous MI (by
self-report) and such with previous stroke according to the population-based stroke register of
the Ludwigshafen Stroke Study (LuSSt) were excluded. Controls were examined in parallel to
recruitment of patients. Both groups were matched for sex and age (± 2 years). Out of the orig-
inal 470 stroke patients and 809 matched controls, saliva samples were additionally taken from
a subpopulation of consecutive 98 stroke cases and 100 controls. Details including study defi-
nitions have been listed previously [28]. Stroke was diagnosed according to the definition of
the World Health Organization [29]. The subtype classification was based on brain imaging
discriminating between ischemic stroke, intracerebral hemorrhage, or subarachnoid hemor-
rhage. Stroke etiology was ascertained using modified stroke criteria as previously described
[30]. Definition of stroke due to large-artery-atherosclerosis (LAA), cardioembolism (CE),
small artery occlusion (SAO), stroke of other determined cause (OTH), and stroke of undeter-
mined cause (UND) was based on TOAST criteria [31]. We additionally addressed “probable
atherosclerotic stroke” (AUT) in accordance with the PERFORM study [32]. Serum and paraf-
fin-stimulated saliva samples were collected and information on smoking habit was included
from the questionnaire.
The study protocol was approved by the ethics committee of the Landesärztekammer
Rheinland-Palatinate and all participants signed an informed consent.
Serum determinations
Determinations of total cholesterol, triglyceride, HDL cholesterol, apoA-I and apoB concen-
trations were carried out by using Abbott Architect reagents (Abbott Laboratories, Abbott
Park, IL, USA) in an accredited clinical laboratory, Forensic Toxicology Unit at the National
Institute for Health and Welfare, Helsinki, Finland. Low density lipoprotein (LDL) cholesterol
was calculated by Friedewald formula. For standardizing measurements, the laboratory has
taken part in Lipid Standardization Program organized by CDC, Atlanta, USA. During the
course of the laboratory measurements of the study samples in 2016, the precision was charac-
terized by the coefficient of variation (mean ± SD) and the accuracy by systematic error (bias)
(mean ± SD). Precision and accuracy were 0.6% ± 0.1 and 0.7% ± 0.5 for total cholesterol,
2.0% ± 0.4 and -2.3% ± 2.0 for triglycerides, 1.3% ± 0.3 and 3.0% ± 1.9 for HDL cholesterol,
1.3% ± 0.6 and 2.9% ± 1.5 for apoA-I and 1.7% ± 0.9 and -3.1% ± 1.7 for apoB, respectively.
Phospholipid transfer activity by PLTP was measured using a lipoprotein-independent
assay as previously described [33]. LBP and sCD14 concentrations were determined by use of
commercial assays from Hycult Biotech (Hycult Biotech Inc, Wayne, PA, USA), catalog num-
bers HK315-01 and HK320, respectively, according to the manufacturer’s suggestions.
LPS-activity and LPS-neutralizing capacity
LPS-activity was determined using the Limulus Amebocyte lysate assay coupled with a chro-
mogenic substrate (Hycult Ltd) on diluted samples (1:10, v/v of endotoxin-free water)
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according to the manufacturer’s instructions. The LPS neutralizing assay was established in
pilot experiments. An appropriate amount of LPS (E. coli 0111:B4, Sigma-Aldrich) to be added
in serum was determined in a range of 0.25 ng/ml-16.0 ng/ml and LPS-activity was measured
further on. The best sensitivity-specificity was observed, when adding 20 pg of LPS (concentra-
tion 5 ng/ml) in serum dilution (5 μl of serum, 4 μl of LPS solution and 41 μl of endotoxin-free
water), which was measured to give 3.67 EU/ml (endotoxin units; mean ± SD; 3.6717 ± 0.339
EU/ml; n = 9) in water. This result was used in the calculations of LPS-neutralizing capacity.
Then, serum samples of cases and controls were diluted, and divided into two. One aliquot
was spiked with the LPS-preparation while the other half aliquot remained untreated. Both
were incubated at 37˚C for 30 minutes, and the LPS activities were measured in accordance
with the manufacturer’s instructions. LPS-NC was calculated as a percentage of neutralized
LPS-activity from the theoretical LPS-activity including the original and the added activities:
1  
LPS spiked




All 198 study participants chewed a piece of paraffin, and at least 2 ml of stimulated whole
saliva was collected. Samples were stored at -70˚C until use for the quantitative analyses of
both oral bacteria and antibodies binding to them. After thawing, the saliva samples were cen-
trifuged at 9300 g for 5 minutes, the supernatants were aliquoted and used for antibody analy-
ses. The pellets were used for quantitative RT-PCR (qPCR) of oral bacteria.
Quantification of oral bacteria with qPCR and A. actinomycetemcomitans
serotyping
The saliva pellets were suspended in 200 ml Tris-EDTA buffer and the extraction of total geno-
mic DNA was performed with the ZR Fungal/Bacterial DNA Kit (Zymo Research) according
to the manufacturer’s instructions. The amounts of A. actinomycetemcomitans and Porphyro-
monas gingivalis were determined with qPCR as previously described [28, 34].
The serotype of A. actinomycetemcomitans in saliva of the bacterium-positive participants
was further examined with A. actinomycetemcomitans serotype-specific qPCR assay as previ-
ously described [14] with minor modifications. qPCR reactions with total volume of 20 μl
contained 1× Kapa SYBR Fast Universal qPCR master mix (Kapa Biosystems, Merck) supple-
mented with ROX reference dye, 2 μl of salivary DNA and 0.2 μM forward and reverse primers
specific to A. actinomycetemcomitans serotypes A-E [14]. Each qPCR plate included a 10-fold
dilution series of standard DNA extracted from a reference strain representing particular sero-
type (ATCC 29523 = serotype A, ATCC 43718 = serotype B, ATCC 33384 = serotype C, IDH
781 = serotype D, IDH 1705 = serotype E). qPCR analyses were performed with the Mx3005P
Real-Time qPCR System (Stratagene) with following steps: 95˚C for 3 min (initial denatur-
ation), 3 s at 95˚C and 20 s at 60˚C (40 cycles). Dissociation curve was generated according to
the default settings of Mx3005P Real-Time qPCR System. The results were analyzed with Stra-
tegene MxPro software. Serotypes were identified based on both the amplification plots and
the dissociation curves specific to each serotype.
Measurement of serum and saliva antibody levels against oral bacteria
Serum and saliva antibody levels against A. actinomycetemcomitans and P. gingivalis were mea-
sured from serum and saliva supernatants by multiserotype-ELISA as described previously
[35]. The antigens were composed of formalin-killed whole bacteria representing several
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serotypes of the species. The strains in the P. gingivalis assays were ATCC 33277, W50, and
OMGS 434, representing serotypes A, B, and C. The strains in the A. actinomycetemcomitans
assays were ATCC 29523, ATCC 43718, ATCC 33384, IDH 781, IDH 1705, and C59A repre-
senting serotypes A, B, C, D, E, and X (non-serotypeable), respectively. Both IgG- and IgA-
class antibody levels were measured. Serum dilutions were 1:100 and 1:200 (P. gingivalis IgA/
IgG and A. actinomycetemcomitans IgA) or 1:1500 and 1:3000 (A. actinomycetemcomitans
IgA). Saliva dilutions were 1:3.6 and 1:36 for all determinations.
Serum antibody levels against different A. actinomycetemcomitans serotypes were deter-
mined also separately as described above. Instead of coating the plates with a mixture of refer-
ence strains, individual strains were used as antigens. The serum dilutions were 1:100 and
1:200 for IgA determinations, and 1:1500 and 1:3000 for IgG determinations. All levels are pre-
sented as ELISA units consisting from mean values of two dilutions determined as duplicates
and normalized according to the reference serum applied on each plate. The interassay coeffi-
cient of variation was <8% for serotypes A IgA, B IgG, C IgG,<10% for serotypes A IgG, D
IgA, D IgG, E IgA, X IgA and<15% for serotypes B IgA, C IgA, E IgG, X IgG.
Statistical methods
Statistical differences between the groups were tested with two-sided t-test and Mann-Whitney
test in continuous and Chi-square test in categorical variables. Variables displaying skewed
distribution were logarithmically transformed before analysis. Pearson’s correlation coefficient
was used for bivariate correlation analyses. Multiple linear regression was used for multivariate
model building. Two-sided level of significance was set to 0.05. Data capture was performed
using EXCEL, while SAS JMP12 and SPSS v. 24 was used for statistical testing and model
building.
Results
The characteristics of cases and controls as well as the laboratory parameters are presented in
Table 1. Serum total cholesterol, HDL cholesterol, apoA-I, and triglyceride concentrations
were significantly (p<0.001) lower in cases similarly as PLTP activity (p = 0.001). Surprisingly,
also serum LPS-activity (p<0.001) and calculated ratios of LPS with LBP and sCD14 were sig-
nificantly (p<0.001) lower in stroke cases compared to controls, while LPS-NC did not differ
(p = 0.056) between cases and controls. The distribution of serum LPS-NC ranging between
51–83% is presented in Fig 1. sCD14 concentrations were slightly but significantly (p = 0.025)
higher in cases than in controls. Dividing the whole stroke group (n = 98) into six subgroups
according to stroke etiology revealed no significant differences (Table 1).
Next, we performed correlation analysis to examine relationships between LPS-activity as
well as LPS-NC and lipid, apolipoprotein, LPS-transfer proteins, and levels of immunoglobu-
lins to A. actinomycetemcomitans in the whole study group (n = 198). Significant positive cor-
relations were found between LPS-activity and triglyceride, total cholesterol, LDL-cholesterol,
and apoB concentrations (Table 2). Furthermore, LPS-activity was significantly correlated
with PLTP-activity (p = 0.001), but not with other LPS-transferring proteins, LBP or sCD14
(Fig 2). Table 2 further shows significant negative correlations between LPS-NC and triglycer-
ide, total cholesterol, LDL-cholesterol, and apoB concentrations as well LPS-activity (coeffi-
cient, p-value: -0.768, <0.001). Positive correlations were found for HDL-cholesterol and IgG
to A. actinomycetemcomitans. From the LPS-transferring proteins, LPS-NC had a significant,
positive correlation only with PLTP activity, but neither with LBP nor sCD14 concentrations
(Fig 2).
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The association of LPS-activity and LPS-NC with other serum parameters was analyzed
with three different linear regression models (Table 3). Triglyceride concentrations (model 1)
and further, LPS-activity (model 2) were the strongest determinants of the LPS-NC. In model
3, HDL-cholesterol concentration was positively, and PLTP-activity and LDL-cholesterol con-
centration negatively associated with the LPS-NC. Neither LBP nor sCD14 associated with
LPS-NC. Similarly, the strongest determinants of LPS-activity were triglyceride, total choles-
terol, LDL-cholesterol, HDL-cholesterol, and apoB concentrations as well as PLTP-activity,
but neither LBP nor sCD14 concentrations.
Table 1. Characteristics and clinical laboratory values according to stroke status.
Stroke status Stroke etiology2
Controls
(n = 100)
Cases (n = 98) P1 AUT n = 18 CEM n = 24 LAA n = 13 SAO n = 28 OTH n = 7 UND n = 8 P3
Age (years) 69 (67.7–70.4) 68.2 (66.2–
70.1)
0.350
Sex (n, % male) 47 (47.0) 45 (45.9) 0.880
Current smokers (n, %) 12 (12.0) 28 (28.6) 0.004







































































































































































































































Presented as mean (95% confidence interval) or number (frequency).
1p-values calculated by t-test or Chi-square test.
2Stroke subtypes are “probable-atherosclerotic” stroke (AUT), cardioembolism (CEM), large-artery-atherosclerosis (LAA), small artery occlusion (SAO), other (OTH)
and undefined (UND) stroke etiology.
3p-values calculated by ANOVA.
https://doi.org/10.1371/journal.pone.0228806.t001
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In addition, the correlations between LPS-activity as well as LPS-NC and two periodontal
biomarker species, P. gingivalis and A. actinomycetemcomitans, were examined. Neither P. gin-
givalis concentration in saliva nor serum or saliva antibody levels against it were significantly
correlated with LPS-NC or LPS-activity (p>0.05, S1 Table). However, serum IgG-class
Fig 1. The distribution of LPS-neutralizing capacity (LPS-NC) of stroke cases and controls. Serum samples of cases
(n = 98) and controls (n = 100) were spiked with 3.67 EU/ml of E. coli LPS and the LPS-neutralizing capacity of the
serum was calculated as 1  
LPS spiked




Table 2. Correlations of LPS-activity and LPS-neutralizing capacity with the clinical laboratory measurements.
Serum LPS-activity (EU/ml) Serum LPS-neutralizing capacity (%)
Coefficient (p-value)1
Triglycerides (mmol/l) 0.881 (<0.001) -0.680 (<0.001)
Total cholesterol (mmol/l) 0.415 (<0.001) -0.335 (<0.001)
HDL cholesterol (mmol/l) -0.142 (0.050) 0.153 (0.034)
LDL cholesterol (mmol/l) 0.194 (0.007) -0.184 (0.010)
ApoA-I (g/l) 0.008 (NS) 0.009 (NS)
ApoB (g/l) 0.506 (<0.001) -0.432 (<0.001)
A. actinomycetemcomitans IgA (ELISA units) -0.051 (NS) 0.068 (NS)
A. actinomycetemcomitans IgG (ELISA units) -0.113 (NS) 0.146 (0.040)
1Pearson correlation.
NS, not significant; EU, endotoxin units
https://doi.org/10.1371/journal.pone.0228806.t002
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antibody level against A. actinomycetemcomitans in a multiserotype-ELISA was a positive pre-
dictor of LPS-NC (p = 0.011) (Table 3) and therefore, A. actinomycetemcomitans was studied
in more detail.
ELISA experiments using individual reference strains representing different serotypes (A to
X) separately as antigens revealed that serotypes D (28.0%), E (16.8%), and A (19.7%) were the
strongest determinants of the serum IgG-class antibody pool to A. actinomycetemcomitans
(Fig 3). The percentages were virtually similar for IgA-class antibodies: 24.4%, 16.8%, and
21.0% for serotypes D, E, and A, respectively. The serum IgA-class antibody against serotype C
was significantly higher in cases than controls (Table 4), whereas both IgA and IgG solely
against the serotype D associated with LPS-NC (Beta 0.385, p = 0.013 and 0.399, p = 0.012).
Other serologies neither differed between the cases and controls nor associated with LPS-NC.
Fig 2. Scatterplots of LPS-activity and LPS-neutralizing capacity (LPS-NC) with LPS transfer proteins.
Correlations between serum LPS-NC and LPS-activity with LPS-transfer proteins PLTP, LBP, and sCD14 is shown in
the whole study population (n = 198). Correlation coefficients and p-values are presented.
https://doi.org/10.1371/journal.pone.0228806.g002
Table 3. Linear regression models for serum LPS activity and LPS-neutralizing capacity.
Dependent variable
Serum LPS activity (EU/ml) Serum LPS-neutralizing capacity (%)
Standardized beta (p-value)
Model 1
Triglycerides (mmol/l) 0.881 (<0.001) -0.680 (<0.001)
Model 2
Triglycerides (mmol/l) 0.736 (<0.001) 0.063 (NS)
LPS (EU/ml) -0.844 (<0.001)
LPS-neutralizing capacity (%) -0.250 (<0.001)
Model 3
HDL cholesterol (mmol/l) -0.251 (0.001) 0.260 (<0.001)
LDL cholesterol (mmol/l) 0.268 (<0.001) -0.265 (<0.001)
PLTP (μmol/h/ml) 0.278 (<0.001) -0.196 (0.005)
LBP (μg/ml) -0.087 (NS) 0.045 (NS)
sCD14 (μg/ml) 0.022 (NS) 0.046 (NS)
IgG to A. actinomycetemcomitans (ELISA units) -0.146 (0.030) 0.171 (0.011)
NS, not significant; EU, endotoxin units
https://doi.org/10.1371/journal.pone.0228806.t003
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Using qPCR, A. actinomycetemcomitans was more frequently detected in the saliva of cases
than in controls (36 vs. 19%, p = 0.007) and its mean concentration was higher (p = 0.023)
(Table 4). The autologous serotype was determined in the saliva samples using serotype-spe-
cific qPCR. Among the 54 (27.3%) A. actinomycetemcomitans -positive subjects, serotype was
detected in 29 (53.7%) saliva samples. Generally one serotype per subject was detected. The
detection rates of the serotypes A to E were 13.0, 15.0, 13.0, 7.5, and 5.5%, respectively (Fig 3).
Serotype D was more frequent in cases compared to controls (4 vs. 0%, p = 0.043), otherwise
there were no differences.
The serotype-specific antibody levels in serum were examined according to the autologous
serotypes in saliva (Fig 4). In serotypes A, B, and C, the serotype-specific serum antibody levels
were significantly (p<0.001) higher against the reference strains representing the correspond-
ing serotype. For example, serum IgA-class antibody levels against A. actinomycetemcomitans
serotype A were highest in those harboring a serotype A strain in saliva compared to those
with another A. actinomycetemcomitans serotype or no A. actinomycetemcomitans. Serotype-
ability or serotypes did not, however, relate to LPS-NC (p>0.05, S1 Fig).
Discussion
We measured a parameter potentially participating in both adaptive and innate immunity
responses: serum LPS-neutralizing capacity. Although LPS-NC did not differ between the
stroke cases and controls, we were able to determine several parameters predicting LPS-NC
levels. In addition to serum lipoproteins, the neutralizing capacity was dependent on PLTP-
activity and antibody levels to A. actinomycetemcomitans. Notably, neither LBP nor sCD14
concentration predicted LPS-NC or LPS-activity.
Fig 3. Relative A. actinomycetemcomitans serotype distributions in the population. Serum IgA- and IgG-class
antibodies against different serotypes (A–X) of A. actinomycetemcomitans were determined using serotype-specific
ELISA. The individual antibody responses to the serotypes were summed up, normalized to 100%, and the proportions
of the responses to each serotype were calculated. The autologous serotype was determined from saliva samples of A.
actinomycetemcomitans–positive subjects (n = 54, 27.3% from the whole population) with qPCR designed for
serotyping. The proportions of each detected serotype are shown.
https://doi.org/10.1371/journal.pone.0228806.g003
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Spiking experiments of serum with LPS have been commonly used to establish suitable
sample processing protocols for the Limulus assay to detect “all LPS-activity present” [23]. In
vivo, LPS is rapidly neutralized in the circulation [36]. In vitro, this neutralizing capacity is
present in serum if not inactivated. To investigate the role of different lipoprotein components
and LPS-transferring proteins in the neutralization process, we set up in pilot experiments a
suitable assay to measure the LPS-NC.
Several reports proposed that LPS not only has a role in atherogenesis but it also may act as
a molecular link between microbiome, low-grade inflammation, and cardiovascular diseases
[37, 38]. Yet, less attention has been payed to investigate how LPS-NC acts in health and dis-
ease. Therefore, we assumed that patients with stroke may have reduced LPS-NC that would
eventually lead to LPS-triggered inflammatory cascade, complement activation, contact path-
way activation, prooxidative stress, and tissue destruction. However, a difference between
stroke cases and controls was not found in the present study. The LPS-preparation used to
spike the sample may cause inter-individual differences in the responses [39]; however, due to
the relative large population, it was not possible to measure samples spiked with different LPS
preparations.
As expected, LPS-NC had a significant positive correlation with HDL-cholesterol, and neg-
ative correlations with triglyceride, cholesterol, and LDL-cholesterol concentrations reflecting
that LPS supplements the lipid moiety of all lipoprotein subclasses, but that HDL is the most
important neutralizer of the LPS-activity [16, 40]. Generally, binding to lipoproteins is the
Table 4. A. actinomycetemcomitans and P. gingivalis bacterial levels and antibodies against them.
Stroke
Sample Species Controls Cases P1
Serum P. gingivalis Multiserotype IgA 0.53 (0.44–0.64) 0.54 (0.45–0.64) 0.894
IgG 21.09 (14.8–30.0) 16.14 (12.6–20.7) 0.227
A. actinomycetemcomitans Multiserotype IgA 1.02 (0.89–1.17) 1.05 (0.89–1.24) 0.780
IgG 1.12 (1.00–1.26) 1.07 (0.95–1.20) 0.582
Serotype A IgA 0.73 (0.63–0.85) 0.86 (0.76–0.98) 0.110
IgG 0.48 (0.41–0.56) 0.53 (0.48–0.58) 0.338
Serotype B IgA 0.48 (0.41–0.55) 0.55 (0.48–0.65) 0.169
IgG 0.22 (0.19–0.25) 0.22 (0.19–0.25) 0.976
Serotype C IgA 0.51 (0.45–0.58) 0.65 (0.57–0.75) 0.008
IgG 0.34 (0.30–0.39) 0.36 (0.32–0.40) 0.521
Serotype D IgA 0.91 (0.81–1.03) 0.92 (0.79–1.07) 0.923
IgG 0.77 (0.68–0.87) 0.70 (0.63–0.79) 0.300
Serotype E IgA 0.60 (0.52–0.68) 0.58 (0.50–0.68) 0.836
IgG 0.45 (0.39–0.51) 0.42 (0.38–0.47) 0.515
Serotype X IgA 0.36 (0.30–0.43) 0.34 (0.27–0.41) 0.596
IgG 0.33 (0.29–0.38) 0.29 (0.25–0.32) 0.114
Saliva P. gingivalis Multiserotype IgA 0.65 (0.58–0.74) 0.53 (0.47–0.61) 0.030
IgG 0.09 (0.07–0.13) 0.05 (0.03–0.07) 0.018
A. actinomycetemcomitans Multiserotype IgA 0.88 (0.78–0.99) 0.93 (0.82–1.06) 0.545
IgG 0.15 (0.12–0.20) 0.12 (0.10–0.16) 0.309
P. gingivalis qPCR (genomes/ml) 1.22 (0.41–3.64) 2.55 (0.86–7.56) 0.326
A. actinomycetemcomitans 4.39 (2.35–8.19) 10.72 (5.45–21.1) 0.023
Presented as mean (95% confidence interval) of log-transformed values. All antibody levels are expressed as ELISA units.
1 P-values from the t-test, except Mann-Whitney test for saliva qPCR result.
https://doi.org/10.1371/journal.pone.0228806.t004
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most important route for LPS detoxification, which thus depends on the lipoprotein subclass
distribution [22, 41]. Most importantly, the connection of LPS-NC and lipoprotein subclasses
might be bidirectional: the inflammatory response driven by active LPS is accompanied by
reduction of lipase activity and induction of triglyceride synthesis leading to increased concen-
trations of very low density lipoprotein (VLDL) cholesterol and triglycerides [40]. Simulta-
neously, HDL undergoes conversion resulting in lower HDL-cholesterol concentrations and
Fig 4. Serum antibody levels against A. actinomycetemcomitans according to the detection of the species and its
serotype in saliva. Serum IgA- (A) and IgG-class (B) antibodies against different serotypes (A–E) of A.
actinomycetemcomitans were determined by ELISA. Presence of A. actinomycetemcomitans in saliva was detected
using qPCR, and its serotype was determined by PCR designed for serotyping. The serotype of the antigen in the
ELISA is presented on the x-axis separately for those whose saliva did not contain A. actinomycetemcomitans, for those
having A. actinomycetemcomitans, but harbouring different serotype in saliva, and for those harbouring the same
serotype in saliva. Number of samples was 198, the columns present the mean values with error bars showing the SE.
The asterisks display the terms of linear trend between the groups according to ANOVA-test for logarithmically
transformed ELISA-units; ��� p<0.001, �� p<0.01.
https://doi.org/10.1371/journal.pone.0228806.g004
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decreased removal of peripheral cholesterol to the liver as further consequence [42]. During
acute-phase response, these alterations will protect the host from further injury and minimize
tissue damage, but in chronic disorders, they may be considered pro-atherogenic. It reasonable
to assume that low LPS-NC exposes the subject to persistent inflammatory responses com-
pared to a physiological situation where LPS activity is promptly neutralized. In the present
study, LPS-NC had a negative correlation with apoB-concentrations paralleling LDL-choles-
terol, but surprisingly no correlation with apoA-I-concentration was observed, although the
C-terminal portion of apoA-I is responsible for LPS-neutralization and displays anti-bacterial
activity [43, 44].
Several proteins in circulation participate in transferring of LPS: LBP, PLTP, and sCD14
[24]. Compared to healthy controls, higher LBP and sCD14 concentrations have been
observed in patients with ischaemic stroke [45], especially in those with a poor short-term
prognosis [3]. Similarly, in the present study we observed elevated sCD14 concentration in the
stroke cases. A recent study also reported higher levels of CD14+ microparticles to be associ-
ated with stroke severity indicating that CD14 may be part of the post-stroke inflammatory
process [46]. This might explain our findings with elevated sCD14 concentrations without dif-
ferences in LPS-NC in stroke cases compared to controls. A long-term follow-up study of the
present patient population will reveal, whether any of the parameters are associated with the
outcome.
LBP and PLTP have the ability to extract LPS from bacterial outer membrane fragments to
HDL particles [24], a process contributing to the clearance of circulating LPS [16, 40]. How-
ever, LBP also promotes LPS binding to membrane-bound or soluble CD14, which primarily
mediates inflammatory responses [47]. It has been speculated that LPS transfer activity of
sCD14 may become more important when serum concentrations of LBP increase and PLTP
decrease during acute infection and inflammation [48]. Thus, the relative concentrations of
LPS-transferring proteins may have a role in determining the fate of LPS, which plausibly
affects the inflammatory response in endotoxemia. However, in the present study neither
sCD14 nor LBP concentrations were associated with LPS-NC or LPS-activity.
Among the potent LPS-transferring proteins LPS-NC was associated only with PLTP-activ-
ity: stronger neutralizing capacity was found in participants with low PLTP-activity. On the
contrary, increased PLTP lipid transfer activity has earlier been measured in both acute and
chronic inflammations [49–51]. It has also been shown that PLTP can protect mice from lethal
endotoxemia [52] independently of the HDL pool [53] by neutralizing LPS and preventing the
growth of gram-negative bacteria [54]. Jänis and co-workers been proposed that PLTP has two
forms regarding the lipid transfer activity, an active and an inactive [55]. In the present study,
we measured only the active form of PLTP, which was related rather to LPS-activity than
LPS-NC. Thus, the multifaceted role of PLTP in infectious and inflammatory disorders
deserves further studies.
LPS is a potent antigen and antibodies are generated against all of its main structural com-
ponents: lipid A, core, and O-antigen. The antibodies are supposed to neutralize LPS-activity,
since immune complexes with LPS are rapidly cleared from the circulation [15]. Therefore, it
is not surprising that the LPS-NC was positively associated with the antibody levels to A. acti-
nomycetemcomitans indicating that these antibodies might neutralize LPS-activity. Since LPS
of A. actinomycetemcomitans contains serotype-specific antigens [13, 56], we further examined
the serology in this population. Especially antibody levels against the serotype D of the species
were associated significantly and directly with serum LPS-NC; this serotype was also more fre-
quently found among stroke cases by direct serotyping. Unfortunately, only a few participants
harbored serotype D and we were not able to do further comparisons. Serotype D has a distinct
O-antigen with repeating tetrasaccharide units, whereas the core and lipid A structure are
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more conserved between serotypes [57, 58]. The lipid moiety of A. actinomycetemcomitans
lipid A has six acyl chains with 14 carbon atoms [57], which is considered having the highest
stimulatory effect on human monocytes, but probably not that active in the Limulus assay
[59]. Considering all the structural and compositional characteristics affecting the reactivity of
any LPS in the Limulus assay [13], the immunogenicity of LPS is impossible to relate to the
LPS-activity or its neutralization. Although the serotyping did not further reveal why A. actino-
mycetemcomitans IgG was correlated with LPS-NC, it cannot be considered only as a feature
of IgG, since a similar correlation was not observed with IgG binding to P. gingivalis.
We previously found that IgA-seropositivity to A. actinomycetemcomitans was associated
with first-ever ischemic stroke in a larger cohort of the Genesis study [60]. These antibodies
have also been found to be associated with increased risk for incident stroke in a 13-year fol-
low-up study [61]. Furthermore, A. actinomycetemcomitans leukotoxin-neutralizing antibod-
ies were associated with lower stroke risk in a 5-year follow-up study [62]. However, in the
present study, the levels of these antibodies did not differ between cases and controls although
the concentration of A. actinomycetemcomitans was higher in the saliva samples of the cases.
This may be due to the limited sample size (n = 198) which was based on the availability of
saliva samples. However, higher concentrations of this A. actinomycetemcomitans have been
observed also earlier in the oral samples of patients suffering from coronary artery disease [63–
65]. A. actinomycetemcomitans is not only associated with increased risk for cardiovascular
diseases, but may also act as an etiologic microbe in endocarditis [66].
To sum up, we did not find significant differences in the LPS-NC between stroke cases and
controls. However, we found that serum LPS-NC is composed of low PLTP-activity, triglycer-
ides and LDL cholesterol, and high HDL cholesterol and IgG binding to A. actinomycetemco-
mitans, whereas apoA-I, LBP, sCD14 or A. actinomycetemcomitans serotypes did not associate
with LPS-NC.
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S1 Fig. LPS-neutralizing capacity according to A. actinomycetemcomitans serotypeability
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bacterium strain, and with a serotypeable strain. B) LPS-NC according to different A. actinomy-
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